Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Using ChEMBL to complement schistosome drug discovery

Padalino, Gilda, Coghlan, Avril, Pagliuca, Giampaolo, Forde-Thomas, Josephine E., Berriman, Matthew and Hoffmann, Karl F. 2023. Using ChEMBL to complement schistosome drug discovery. Pharmaceutics 15 (5) , 1359. 10.3390/pharmaceutics15051359

[thumbnail of Using ChEMBL to Complement Schistosome Drug Discovery PUBLISHED.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (3MB) | Preview
License URL:
License Start date: 28 April 2023


Schistosomiasis is one of the most important neglected tropical diseases. Until an effective vaccine is registered for use, the cornerstone of schistosomiasis control remains chemotherapy with praziquantel. The sustainability of this strategy is at substantial risk due to the possibility of praziquantel insensitive/resistant schistosomes developing. Considerable time and effort could be saved in the schistosome drug discovery pipeline if available functional genomics, bioinformatics, cheminformatics and phenotypic resources are systematically leveraged. Our approach, described here, outlines how schistosome-specific resources/methodologies, coupled to the open-access drug discovery database ChEMBL, can be cooperatively used to accelerate early-stage, schistosome drug discovery efforts. Our process identified seven compounds (fimepinostat, trichostatin A, NVP-BEP800, luminespib, epoxomicin, CGP60474 and staurosporine) with ex vivo anti-schistosomula potencies in the sub-micromolar range. Three of those compounds (epoxomicin, CGP60474 and staurosporine) also demonstrated potent and fast-acting ex vivo effects on adult schistosomes and completely inhibited egg production. ChEMBL toxicity data were also leveraged to provide further support for progressing CGP60474 (as well as luminespib and TAE684) as a novel anti-schistosomal compound. As very few compounds are currently at the advanced stages of the anti-schistosomal pipeline, our approaches highlight a strategy by which new chemical matter can be identified and quickly progressed through preclinical development.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Pharmacy
Publisher: MDPI
ISSN: 1999-4923
Funders: Wellcome Trust
Date of First Compliant Deposit: 7 May 2023
Date of Acceptance: 26 April 2023
Last Modified: 09 Sep 2023 05:22

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics